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Abstract: Almost 47 million people suffer from dementia worldwide, with an estimated 
new case diagnosed every 3.2 seconds. Alzheimer’s disease (AD) accounts for approximately 
60%–80% of all dementia cases. Given this evidence, it is clear dementia represents one of the 
greatest global public health challenges. Currently used drugs alleviate the symptoms of AD 
but do not treat the underlying causes of dementia. Hence, a worldwide quest is under way to 
find new treatments to stop, slow, or even prevent AD. Besides the classic targets of the oldest 
therapies, represented by cholinergic and glutamatergic systems, β-amyloid (Aβ) plaques, and 
tau tangles, new therapeutic approaches have other targets. One of the newest and most prom-
ising strategies is the control of reactive gliosis, a multicellular response to brain injury. This 
phenomenon occurs as a consequence of a persistent glial activation, which leads to cellular 
dysfunctions and neuroinflammation. Reactive gliosis is now considered a key abnormality in 
the AD brain. It has been demonstrated that reactive astrocytes surround both Aβ plaques and 
tau tangles. In this condition, glial cells lose some of their homeostatic functions and acquire a 
proinflammatory phenotype amplifying neuronal damage. So, molecules that are able to restore 
their physiological functions and control the neuroinflammatory process offer new therapeutic 
opportunities for this devastating disease. In this review, we describe the role of neuroinflam-
mation in the AD pathogenesis and progression and then provide an overview of the recent 
research with the aim of developing new therapies to treat this disorder.
Keywords: reactive gliosis, astrocyte, microglia, Alzheimer’s disease
Introduction
Dementia is a chronic condition characterized by a progressive cognitive impairment 
that leads to functional disability.1 In 2015, it was estimated that approximately 47 
million people worldwide were affected by dementia, and this number is expected to 
increase, reaching 131.5 million by 2050.2 As such, it represents a veritable public 
health challenge. Alzheimer’s disease (AD), a pathology first described by Alois 
Alzheimer in 1907,3 is the most frequent cause of dementia in elderly. Knowledge 
about the etiology and pathogenesis of the disease is continuously updated,4 but there 
are still limitations in diagnostic capability5 and in the discovery of pharmacological 
treatments that would be able to stop or better prevent the disease. At present, AD is 
incurable. Despite the huge amount of preclinical and clinical investigation, medica-
tions currently used provide only a modest symptomatic relief to a subset of patients 
and do not treat the underlying causes of this disease. The reasons for this failure 
are probably due to the scant knowledge of the cellular and molecular mechanisms 
implicated in AD pathogenesis and of the approved therapies that coarsely affect both 
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cholinergic and glutamatergic neurotransmission. Conversely, 
many of the new drugs in development aim to modify the 
disease process itself by impacting one or more of the many 
wide-ranging brain changes caused by AD. These changes 
offer potential targets for new drugs to stop or slow down 
the disease progression. It is now well recognized that AD 
is a multifactorial disorder. It is pathologically character-
ized by widespread oxidative stress, mitochondrial damage, 
glutamate excitotoxicity, neuroinflammation, neurofibrillary 
tangle (NFT) formation, and β-amyloid (Aβ) deposition 
creating senile plaques (SPs).6 These latter are constituted 
by Aβ peptide, and their genesis is followed by intracellular 
deposition of NFTs,7 as a consequence of tau protein hyper-
phosphorylation. The results are synaptic and neuronal dys-
function and loss.8 Over the years, it has been demonstrated 
that other factors play an important role in the pathogenesis 
and progression of AD. Among them, the key role of neuro-
inflammation has been affirmed.9
Physiologically, the inflammatory process is aimed at 
controlling injuries through several mechanisms to repair 
tissues.10 However, an increasing amount of literature con-
firms its role in the pathogenesis and exacerbation of AD.11–14 
Inflammation acts to remove both the initial cause of the 
infliction and to eliminate the destroyed tissues and dead 
cells resulting from the original injury.
In fact, inflammation is emerging as the real cause of 
the associated disease, more than a mere contribution to the 
exacerbation of tissue damage. Indeed, some studies have 
revealed that the injection of lipopolysaccharide in transgenic 
mice induces neuroinflammation, triggering intracellular Aβ 
deposit and tau phosphorylation.15,16
The molecular processes are not necessarily the primary 
events. The inflammatory machine could also be triggered 
by traumatic or surgical causes. The microglial priming 
model suggests that the presymptomatic AD pathology, 
characterized by low levels of proinflammatory mediators, 
can act on microglia for long periods of time.17 Furthermore, 
stress, inflammation, and infection can operate as secondary 
triggers, causing changes in these primed cells: they reach 
an activated state establishing an inflammatory response 
contributing to AD pathogenesis.18
From an immunological point of view, the central ner-
vous system was always seen as a highly protected tissue, 
exposed to inflammatory phenomena solely in cases of 
infection or disruption of the blood–brain barrier (BBB). 
Nowadays, we know that there are several cells expressing 
pattern recognition receptors able to induce inflammatory 
signaling pathways.13 These pattern recognition receptors 
can recognize molecular signals of microbial molecules, 
called pathogen-associated molecular patterns, as well 
as endogenous damage-associated molecular patterns 
(DAMPs), that typically accumulate in infected tissues. 
DAMPS are present in diseased brains as misfolded proteins 
(eg, SPs and NFTs), aggregated peptides, or nucleic acids.19 
It is clear that DAMPs can trigger neuroinflammation by 
deflecting proinflammatory reactions from their helpful 
purpose, and this is the reason why our way of viewing 
neurodegenerative diseases has changed over the years.
The role of the neuroinflammatory process is not exclu-
sively attributable to innate immunity (which in the brain 
is constituted by microglia), but it is also caused by other 
brain resident cells that constitute, in one word, macroglia 
(ie, astrocytes, NG2-positive cells, and oligodendrocytes), 
as well as endothelial cells and neurons.20–23
Hence, it is clear that there are many characters involved 
in this inflammatory process. Thus, a better knowledge of 
the mechanisms underlying the role of neuroinflammation 
in AD can be an excellent starting point for the development 
of molecules able to counteract it.
The pathophysiology of 
neuroinflammation and its role in 
Alzheimer’s disease
Even if Aβ deposits can alone induce an inflammatory 
response that subsequently leads to AD development, it is 
well established that the neuroinflammatory pathophysiology 
is more complex and driven by the activation of different 
brain cells. In particular, growing evidence suggests that 
this phenomenon is mainly supported by glial cells, which 
respond quickly to brain injuries, activating a series of 
repair mechanisms to restore brain physiology. Glial cells 
are nonexcitable cells of the central nervous system. These 
cells are a highly heterogeneous population, responsible for 
many important brain functions.24 While microglia acts as the 
first form of immune defense in the brain, astrocytes are an 
essential neurosupportive cell type. Indeed, astrocytes finely 
control the environment by regulating pH, ion homeostasis, 
oxidative stress, and blood flow.25,26 These cells together with 
microglia, oligodendrocytes, neurons, pericytes, and endo-
thelial cells constitute the neurovascular unit, responsible for 
the proper functioning of the BBB.27 In addition, astrocytes 
contribute importantly to synaptogenesis and dynamically 
modulate information processing and signal transmission, 
regulate neural and synaptic plasticity, and provide trophic 
and metabolic support to neurons.28,29 Interestingly, data from 
animal models and human autopsy revealed that both SPs 
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and NFTs cause an immune response in the brain and colo-
calize close to activated glial cells. Astrocyte and microglia 
acquire a reactive phenotype20 and rapidly act in response to 
pathology undergoing important changes in their morphology 
and functioning.30,31 Such an activation is fundamentally a 
protective response aimed at removing injurious stimuli. The 
neuroprotective action of reactive astrocytes takes place by 
modulating Aβ-mediated neurotoxicity, degrading, internal-
izing, and removing Aβ, thus creating a protective barrier that 
surrounds plaques.32–34 However, uncontrolled and prolonged 
activation goes beyond physiological control, and detrimental 
effects override the beneficial ones. In this condition, glial 
cells foster neuroinflammatory response, accounting for 
the synthesis of different cytokines and proinflammatory 
mediators.35,36 This condition is called reactive gliosis and is 
a characteristic event of AD brains (Figure 1). For example, 
activated microglia reduces Aβ accumulation by increasing 
its phagocytosis, clearance, and degradation,37 as well as by 
secreting factors such as the glia-derived neurotrophic factor, 
helpful for neuronal survival.38 Recently, microglia functions 
aimed at Aβ clearance were attributed to the presence of 
triggering receptor expressed on myeloid cells 2 (TREM2), 
a transmembrane receptor;39,40 indeed not long ago, TREM2 
was identified as a risk gene for AD.41,42 It is reasonable to 
think that this association between TREM2 and AD is due 
to the many functions carried out through the activation of 
different pathways ranging from phagocytosis to encouraging 
survival and proliferation, and finally promoting secretion of 
cytokines and chemokines.43–45
Even astrocytes play an important role in the maintenance 
of the cerebral homeostasis. These cells are responsible for 
the proper functioning of the BBB, provide nutrients to 
neurons, preserve the extracellular ion balance, and remove 
and degrade Aβ.46 However, glial functions are deeply 
altered whenever tissue physiology is not restored. In these 
circumstances, the inability to counteract Aβ and NFTs 
accumulation constantly stimulates the machinery needed 
to remove debris; in this way, astrocytes actively support 
inflammation.47,48
Several studies demonstrated that their action becomes 
relevant from early stages of the pathogenic process, turning 
to a cycle independent from Aβ presence, neural dysfunction, 
cell death, and disease progression.49–51 The resulting chronic 
inflammation is due to the release of proinflammatory mol-
ecules that act not only in an autocrine manner, allowing the 
perpetuation of the reactive gliosis, but also in a paracrine 
one, the main cause of the neuronal death that increases the 
pathological damage.52,53 Neuronal death is determined by the 
release of not only inflammatory mediators, but also of reac-
tive oxygen species, nitric oxide (NO), proteolytic enzymes, 
complement factors, and/or excitatory aminoacids.54 At 
the molecular level, the release of these mediators affects 
neuron–glia crosstalk, influencing redox enzyme sensors, 
receptors, and transcription factors.55
In physiological conditions, microglia protects the brain 
from pathogens, and, together with macroglia, helps maintain 
homeostasis of the tissue. In AD, all these cells became more 
reactive and change their morphology  surrounding SPs.56 
Blood vessel
Blood vessel
Activated microglia
Reactive astrocyte
BBB dysfunction
Neuronal death
Proinflammatory mediators
Anti-inflammatory mediators
ROS
NO
Synaptic loss
Intracellular Aβ
Tau aggregation
Microglia
Astrocyte
Neuron
Aβ
Proinflammatory mediators
S100Β
Figure 1 Schematic representation of glial activation.
Notes: As a result of brain damage (eg, brain trauma, ischemia, Aβ accumulation, NFTs, etc) microglia and astrocytes acquire a so-called reactive phenotype losing their 
physiological functions. Morphofunctional changes, loss of three-dimensional network, and neurovascular unit alterations contribute to cause a homeostatic imbalance. 
Moreover, after activation, these cells produce a wide range of cytokines and proinflammatory mediators, leading to chronic inflammation. Even if the initial intent of these 
modifications is reparative, such long-lasting and uncontrolled activation causes further neurodegeneration.
Abbreviations: ROS, reactive oxygen species, NO, nitric oxide; Aβ, β-.amyloid; NFTs, neurofibrillary tangles; BBB, blood–brain barrier.
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This is possible because of the presence of proinflammatory 
receptors on their surface. Microglia is able to identify and 
bind Aβ oligomers and fibrils and the amyloid precursor 
protein (APP)57 through a large number of receptors, includ-
ing scavenger receptor class A type 1, MARCO, scavenger 
receptor class B member 1, CD36, and the receptor for 
advanced glycation end product,58,59 G protein-coupled 
receptors formyl peptide receptor 2 60 and chemokine-like 
receptor 1,61 toll-like receptors (TLRs) TLR2,62 TLR4, and 
the CD14 coreceptor, and α6β1 integrin.63 The outcome of 
the bond between Aβ and these receptors is the production 
of inflammatory mediators such as cytokines (interleu-
kin [IL]-1α, IL-1β, IL-6, IL-8, IL-12, IL-18, and IL-23, 
interferon (IFN)-γ, tumor necrosis factor [TNF]-α, and 
granulocyte-macrophage colony-stimulating factor [GM-
CSF]),64,65 chemokines (monocyte chemotactic protein 1 
(MCP1), MCP-113, fractalkine),66,67 chemoattractant pro-
teins, prostaglandins, complement factors, thromboxanes, 
pentraxins, NO, reactive oxygen species, leukotrienes, 
proteases, protease inhibitors, adhesion molecules (inter-
action between CD40-CD40 ligand CD40L),68 coagulation 
factors, and C-reactive protein, most of which are detectable 
in AD animal and/or in the brain or cerebrospinal fluid of 
AD patients.25,69,70 However, glial cells are also capable of 
producing some regulatory cytokines, such as IL-10 and 
transforming growth factor-β (TGF-β), but in AD their 
release is modified, exacerbating the disease.71–73 Among 
anti-inflammatory factors, we also recall the cluster of dif-
ferentiation-200 (CD200) regulated by the anti-inflammatory 
IL-4 and expressed by neurons, T- and B-cells, whose recep-
tor is expressed by glia. Both AD patients and mouse models 
show an age-related or Aβ-induced CD200 reduction.74–76
Upstream of cytokines production is the activation of the 
nuclear factor-kappa B (NF-κB) pathway,77 and the subse-
quent activation of mitogen-activated protein kinase (MAPK) 
pathways, whose proinflammatory gene expression is Aβ 
dependent.78 Extracellular signal-regulated protein kinases 
(ERKs), stress-activated protein kinases c-Jun NH2-terminal 
kinase (JNK), and p38 constitute the set of MAPKs whose 
action is exerted both in the cytoplasm and in the nucleus, 
thereby phosphorylating transcription factors. For example, 
p38 can contribute to neuroinflammation by inducing TNF-α 
gene transcription, which increases the activator protein-1 
(AP-1) activity,79 besides being directly responsible for tau 
phosphorylation.80
In turn, proinflammatory mediators increase the activ-
ity and the products of amyloidogenic pathway, especially 
Aβ
(1–42)
. For instance, the γ-secretase cell-based assays 
showed that TNF-α, IL-1β, and IFN-γ cause the initiation 
of APP cleavage through the MAPK pathway,81 and a more 
recent study demonstrated that NF-κB signaling, activated 
by TNF-α, results in an increased Aβ synthesis driven by the 
β-secretase (BACE-1) transcription.82
To the vicious circle driven by cytokines and MAPKs,83,84 
the resulting activation of the complement cascade has to be 
added,85 as well as the induction of proinflammatory enzymes, 
such as cyclooxygenase-2 (COX-2)86 and the inducible nitric 
oxide synthase (iNOS).87 Induction of these enzymes may 
also be linked to the excessive release of S100B (ββ form 
of the S100), a neurotrophin expressed by activated astro-
cytes,88 which is able to induce NF-κB activation,89 as well as 
encourage tauopathy.23 Two more proinflammatory proteins, 
implicated in the pathophysiology of AD, belong to the S100 
family: S100A9 and S100A12. These proteins, produced by 
activated microglia and macrophages, are increased in AD 
brain and are responsible for protein complex formation.90,91 
S100A9 is present within SPs and Aβ deposits surrounding 
blood vessels, and it is also abundant in tissues neighboring 
Aβ deposits, confirming that increased S100A9 levels can 
stimulate peptides aggregation and deposition.92
Studies report that tau hyperphosphorylation is directly 
affected by inflammatory mediators, including the cyclin-
dependent kinase 5 (CDK5):93 IL-6 stimulates neuronal 
protein p35, which in turn is responsible for the kinase 
activation that can act on tau.94 CDK5 is not the only kinase 
related to neuroinflammation. Recently, the role of protein 
kinase 2 (CK2, former casein kinase II) has been described. 
In fact, CK2 immunopositive astrocytes have been found to 
be associated with amyloid deposits in AD brains, suggesting 
its involvement in the neuroinflammatory response.95
Inflammatory mediators, in particular cytokines, are also 
responsible for increased BBB permeabilization driven by 
chemokines, allowing leukocyte penetration in the brain.96,97 
This is possible because of altering the resistance of tight 
junctions, upregulation of cytokines expression, and COX-2 
transcription in endothelial cells.98 For example, IL-6, IL-10, 
IL-13, and prostaglandins stimulated by lipopolysaccharide 
may increase the influx of Aβ across the BBB, besides 
upregulating APP processing in the brain.99,100
Another mechanism underlying the pathogenic process 
led by neuroinflammation is the blockage of neurogenesis, 
which is inhibited by some proinflammatory cytokines such 
as IL-6, TNF-α, and IL-18, responsible for neural progenitor 
cells death, and inhibition of their differentiation.101 Interest-
ingly, these cells are located in the subgranular layer of the 
dentate gyrus of the hippocampus, in the subventricular zone 
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of the lateral ventricles, and amygdala – areas mainly affected 
by AD and cognitive impairment.102
One of the still poorly explored mechanisms that might 
govern the relationship between AD and neuroinflammation, 
but definitely is in charge of the neurodegenerative processes, 
involves the glycogen synthase kinase-3 (constitutively active 
serine/threonine protein kinase) pathway.103 This idea comes 
from the observation of the results obtained by blocking this 
kinase, which causes an increase of the anti-inflammatory 
IL-10 and a decrease of proinflammatory cytokines as a 
consequence of TLRs stimulation and NO production.104–106
The salient events reported in this paragraph are sum-
marized in Figure 2.
Neuroinflammatory targets in 
Alzheimer’s disease
Because of the knowledge acquired so far and the fail-
ure of so many antiamyloid trials, scientific interest has 
shifted to other features of neurodegeneration including 
neuroinflammation.107
Evidence mentioned in “The Pathophysiology of Neuro-
inflammation and Its Role in Alzheimer’s Disease” section 
shows how neuroinflammation is driven by a large number 
of events apparently different but strongly dependent one on 
the other.108 For this reason, it is difficult to identify the best 
target upon which to act. Recently, much work has been done, 
but much more research still needs to be done.
It is now clear that the AD neurodegenerative process is 
also orchestrated by proinflammatory cytokines and their 
receptors, which therefore become promising targets on 
which to focus by means of different approaches. Blocking 
gene expression of cytokines, releasing or binding their recep-
tors, or better regulating the functioning of cells implicated in 
the neuroinflammation are definitely strategies still in explo-
ration.109 The possibility of of reducing tau kinase activity and 
oligomeric and fibrillary Aβ accumulation by  neutralizing 
Brain injuries
Glial activation
Morphofunctional changes
Synaptic dysfunction
Homeostatic imbalance
Neurovascular unit dysfunction
Loss of three-dimensional network
BBB dysfunction
Neuroinflammation
Acquisition of a reactive phenotype
S100B/GFAP/IBA1/CD11/b
           IL-1α/IL-1β/IL-6/IL-8/IL-12/IL-18/IL-23/IFN-γ/GM-CSF/
             MCP1/MCP-113/fractalkine/chemo-attractant proteins/
               complement factors/thromboxanes/prostaglandins/
leukotrienes/pentraxins/NO/ROS/proteases/protease inhibitors/
adhesion molecules/coagulation factors/C-reactive protein, etc
SCARA-1/MARCO/SCARB-1/CD36
RAGE/GPCRs/FPR2/CMKLR1
TLR2/TLR4/CD14/α6β1 integrin
- Hypertrophic astrocyte
- Astrocyte endfeet retraction
- Amoeboid microgliaBinding receptors for Aβ and APP
Proinflammatory mediators and cytokines
N
e
u
r
o
n
a
l
 
d
e
a
t
h
Injuries removal Recovery(trauma, surgery, oxidative 
stress, SPs, NFTs,
 toxics, etc)
Figure 2 Integrated pathways between glial activation, neuroinflammation, and neuronal death after brain injury.
Notes: Whenever a brain injury occurs, glial activation takes place with the aim of removing injurious stimuli. To this aim, activated cells undergo a series of morphofunctional 
changes and acquire a reactive phenotype. Activation causes, among other things, glial hypertrophy, astrocyte endfeet retraction, and gain of amoeboid microglial structure. 
These changes, if not stopped, can induce synaptic dysfunction, homeostatic imbalance, neurovascular unit dysfunction, loss of three-dimensional network, and BBB 
dysfunction. In addition, reactive microglia and astrocytes release a wide range of proinflammatory mediators aimed at removing the primary injury. The occurrence of a 
reactive state is very probably a protective response. However, uncontrolled and prolonged activation goes beyond physiological control, and detrimental effects override 
the beneficial ones. Solid arrows indicate complete pathways. Dashed arrows indicate pathways that that occur partially or do not.
Abbreviations: BBB, blood–brain barrier; Aβ, β-amyloid; NFTs, neurofibrillary tangles; SCARA-1, scavenger receptor class A Type 1; SCARB-1, scavenger receptor class B 
member 1; RAGE, receptor for advanced glycation end product; GPCRs, G protein-coupled receptors; FPR2, formyl peptide receptor 2; CMKLR1, chemokine-like receptor 
1; TLRs, toll-like receptors; IL, interleukin; IFN-γ, interferon-γ; GM-CSF, granulocyte-macrophage colony-stimulating factor; NO, nitric oxide; ROS, reactive oxygen species; 
SPs, senile plaques; IBA1, ionized calcium-binding adapter molecule 1; CD, cluster of differentiation.
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IL-1β or  TNF-α/TNF-α receptor through antibodies has been 
demonstrated in murine models of AD.64,110–113 In this context, 
the role of molecules with anti-inflammatory properties (such 
as minocycline) that are able to decrease astrocyte release of 
proinflammatory cytokines and reduce both tau and amyloid 
pathogenesis,114 as well as improve AD behavioral symptoms, 
is not less important.115
Interestingly, both in vitro and in vivo studies have shown 
that pharmacological inhibition of COX-2 and inducible NO 
synthase has positive outcomes.38,116–120
Lastly, in AD models it was observed that it is possible 
to obtain satisfactory results by modulating kinases that are 
not only directly related to tau hyperphosphorylation but 
also to neuroinflammation. One example is the modulation 
of glycogen synthase kinase-3β. Experimental studies have 
shown that it is possible to exert anti-inflammatory effect by 
inhibiting this enzyme, giving us another potential therapeutic 
target to consider.87,88,121
Currently available products 
and products in research and 
development focusing on 
neuroinflammatory targets
In the past decades, several epidemiological and clinical 
studies were carried out to demonstrate the neuroprotec-
tive potential of several nonsteroidal anti-inflammatory 
drugs.122,123 After the pioneering work with indometacin 
demonstrated the ability to restore cognitive functions in the 
enrolled subjects, many other clinical trials have shown only 
unsatisfactory results.124–127 Since the failure of trials with 
classical nonsteroidal anti-inflammatory drugs, scientists 
tested COX-2-selective compounds effects. Once again, 
results were disappointing.128,129 Evidence from a clinical 
trial with naproxen suggests its ability to reduce tau and Aβ 
levels in cerebrospinal fluid and plasma.130 AD is a multifac-
torial disease and the inflammatory outcome, driven by glial 
activation, depends on the context and on the stage of the 
pathology. For these reasons, an ideal anti-inflammatory com-
pound should be able to control the detrimental effects and, 
at the same time, preserve the physiological glial activation.
An alternative and recent therapeutic approach is repre-
sented by nutraceuticals (eg, curcumin, apigenin, docosa-
hexaenoic acid, resveratrol, and n-3 fatty acids).131–134 Despite 
encouraging preclinical results, the success rate in humans 
has been very low.135
Complex results were obtained after vaccinating AD 
patients against Aβ and NFTs. A large number of studies 
have been done in this field, and promising data were obtained 
in preclinical models. Unfortunately, these encouraging 
findings were not replicated in clinical trials, and promising 
vaccines were stopped because of adverse effects such as 
meningoencephalitis.136 Some of these studies revealed that 
immunization halts glial activation.137 By the physiological 
importance of this phenomenon, this is probably why the 
immunization has caused severe adverse reactions.
Presently, several competing hypotheses (especially related 
to time of intervention) may help explain the failure of translat-
ing preclinical studies into the clinical ones, but so far there 
is no way to confirm which of these explanations is correct.
Future research direction
The pathogenic role of neuroinflammation in AD is now 
well recognized and accepted. Nevertheless, the underlying 
mechanisms have not been sufficiently elucidated. Several 
factors contribute to this failure. First of all, there is a lack 
of adequate preclinical models that best mimic the disease 
and, in particular, the processes of glial activation and 
neuroinflammation. Then, another important factor is the 
comprehension of the role of each cellular component in 
the inflammatory process, for example, the identification 
of cell-specific biomarkers. Indeed, specifically clarifying 
changes in both immune system and inflammatory machinery 
would make available different pathways for pharmacological 
manipulations aimed at delaying the onset and/or the pro-
gression of the disease. Finally, it is important to define the 
inflammatory stages to correlate each phase to AD progres-
sion and to clarify which processes are protective and which 
ones are detrimental.
The achievement of these goals will allow scientists to 
practice many other experimental approaches. The hope is to 
get satisfactory results from clinical studies with compounds 
that have been successful in vitro, ex vivo, and/or in vivo 
experiments, such as the administration of molecules like 
acetylpuerarin,138 edaravone,139 palmitoylethanolamide,38 
N-[2-(4-hydroxyphenyl)ethyl]-2-(2,5-dimethoxyphenyl)-
3-(3-methoxy-4-hydroxyphenyl) acrylamide (compound 
FLZ),140 oleuropeinaglycone,141 oridonin,142 protocatechuic 
acid,143  resveratrol,110 rutin,144 or immunotherapies145,146 and 
vaccinations.147
Conclusion
Growing evidence confirms that neuroinflammation, finely 
orchestrated by neuronal, glial, and immune components, 
is a contributing cause of Aβ aggregation, tau hyperphos-
phorylation, and neuronal damage and death. The resulting 
production of cytokines and proinflammatory molecules has 
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initially a neuroprotective role, but subsequently becomes the 
cause of further neurodegeneration.
Unfortunately, because of the lack of appropriate animal 
models, we still lack a complete understanding of the relation-
ship between inflammatory process stages and AD progres-
sion. This could explain, at least in part, the unsuccessful 
results of clinical trials performed with anti-inflammatory 
molecules whose efficacy was significantly proven in pre-
clinical investigations.
Therefore, future experimental studies must intensively 
investigate the intricate paths of the neuroinflammatory 
process and define the best time to control it. In this way, 
it will be possible to achieve more focused and functional 
therapeutic strategies in the hope of not only alleviating but 
also modifying AD progression.
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